inWhite tw_white-black
MoreMenu
CloseWhite
inWhite tw_white-black

News

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026

Asgard Therapeutics strengthens its Board of Directors and Advisory Board with leading experts in drug development and cancer immunotherapy

Asgard Therapeutics appoints immunology expert Shane Olwill as Chief Development Officer

Asgard Therapeutics’ study published in Science showing proof-of-concept and strong anti-tumor responses via in vivo cell reprogramming with lead program AT-108

Asgard featured on the report from SwedenBIO covering Swedish Drug Discovery and Development Pipeline 2020

Posted 26 June, 2020